Rivaroxaban as monotherapy in patients with venous thromboembolism

Krivoshchekov E.P.

V.D. Seredavin Samara Regional Clinical Hospital, Samara State Medical University, Ministry of Health of the Russian Federation, Samara, Russia

Migunov I.A.

V.D. Seredavin Samara Regional Clinical Hospital, Samara State Medical University, Ministry of Health of the Russian Federation, Samara, Russia

Romanov V.E.

V.D. Seredavin Samara Regional Clinical Hospital, Samara State Medical University, Ministry of Health of the Russian Federation, Samara, Russia

Rivaroxaban as monotherapy in patients with venous thromboembolism

Authors:

Krivoshchekov E.P., Migunov I.A., Romanov V.E.

More about the authors

Journal: Pirogov Russian Journal of Surgery. 2016;(10): 61‑65

DOI: 10.17116/hirurgia20161061-65

Read: 2100 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Krivoshchekov EP, Migunov IA, Romanov VE. Rivaroxaban as monotherapy in patients with venous thromboembolism. Pirogov Russian Journal of Surgery. 2016;(10):61‑65. (In Russ.)
https://doi.org/10.17116/hirurgia20161061-65

Подписка 2025-2 (Pirogov Russian Journal of Surgery)

Использование инфографики авторами научных работ

Close metadata

Venous thromboembolism is the major cause of death and important health problem. Anticoagulants is the mainstay modality of VTE treatment and rivaroxaban was the first novel anticoagulant approved for VTE treatment and secondary prevention in Russia. Current study was designed to assess efficacy and safety of rivaroxaban from the first day of VTE treatment. There were 78 patients in control group treated with LMWH and VKA, and 46 patients in the rivaroxaban group. Treatment duration was not less than 3 months. After 3 months there were 3 (3.85%) patients in control group and 1 (2.2%) patient in the rivaroxaban group with thrombus deterioration. Bleeding complications were observed in 6 (7.7%) patients in LMWH/VKA group and in 2 (4.3%) patients in the rivaroxaban group. In conclusion, results of the study show favorable benefit profile of rivaroxaban in VTE patients and rivaroxaban could be considered as initial therapy.

Keywords:

deep vein thrombosis

oral anticoagulant

pulmonary embolism

rivaroxaban

Authors:

Krivoshchekov E.P.

V.D. Seredavin Samara Regional Clinical Hospital, Samara State Medical University, Ministry of Health of the Russian Federation, Samara, Russia

Migunov I.A.

V.D. Seredavin Samara Regional Clinical Hospital, Samara State Medical University, Ministry of Health of the Russian Federation, Samara, Russia

Romanov V.E.

V.D. Seredavin Samara Regional Clinical Hospital, Samara State Medical University, Ministry of Health of the Russian Federation, Samara, Russia

List of references:

Bokeriya L.A., Mikhailichenko M.V., Kovalenko V.I. Metody profilaktiki tromboza glubokikh ven posle operatsii po povodu varikoznoi bolezni ven nizhnikh konechnostei. Angiologiya i sosudistaya khirurgiya. 2014;20:2:53-54.
Kuz'min A.V., Bogdanova L.A. Organizatsiya profilaktiki venoznykh tromboembolicheskikh oslozhnenii s ispol'zovaniem klinicheskoi informatsionnoi sistemy DOKA+ v regional'noi klinicheskoi bol'nitse. Flebologiya. 2014;6:3:6-9.
Krivoshchekov E.P., Dmitrieva I.A., Gubanova T.A. Flebologicheskaya pomoshch' bol'nym s oslozhnennymi formami khronicheskoi venoznoi nedostatochnosti na ambulatornom etape. Flebologiya. 2014;2:8:117-118.
Krivoshchekov E.P., Romanov V.E., Dmitrieva I.A. Konservativnoe lechenie oslozhnennykh form khronicheskoi venoznoi nedostatochnosti na fone sakharnogo diabeta. Flebologiya. 2014;2:8:118.
Krivoshchekov E.P., Dmitrieva I.A., Alekseev A.V., Mel'nik N.V. Khirurgicheskoe lechenie bol'nykh s oslozhnennymi formami varikoznoi bolezni nizhnikh konechnostei v usloviyakh angiologicheskogo dnevnogo statsionara. Vestnik vserossiiskogo obshchestva spetsialistov po mediko-sotsial'noi ekspertize, reabilitatsii i reabilitatsionnoi industrii. 2013;3:94-99.
Savel'ev V.S., Kirienko A.I., Zolotukhin I.A., Andriyashkin V.V. Profilaktika posleoperatsionnykh venoznykh tromboembolicheskikh oslozhnenii v rossiiskikh statsionarakh. Flebologiya. 2010;3:3-8.
Kirienko A.I., Savel'ev B.C., Chazov E.I., Gusev E.I., Rossiiskie klinicheskie rekomendatsii po diagnostike, lecheniyu i profilaktike venoznykh tromboembolicheskikh oslozhnenii. Flebologiya. 2010;5-6.
Kirienko A.I., Stoiko Yu.M., Bogachev V.Yu. Rossiiskie klinicheskie rekomendatsii po diagnostike, lecheniyu i profilaktike venoznykh tromboembolicheskikh oslozhnenii. Flebologiya. 2015.
Shilova A.N., Karpenko A.A., Karmodonova N.A., Starosotskaya M.V., Klevanets Yu.E. Osobennosti terapii TELA pri gematogennoi trombofilii. Angiologiya i sosudistaya khirurgiya. 2914;19:3:71-73.
Angelli G. Current issues in anticoagulation. Patophysiol Haemost Tromb. 2005;2-9. doi: 10.1159/000083078
Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S for the EINSTEIN investigators. Oral rivaroxaban for symptomatic venous thromboembolism. Engl Med. 2010;2499-2510. doi: 10.1056/NEJMoa1007903
Dmitrieva I, Krivoshchekov E. Flebological Help patients with complicated forms of chronic venous insufficitncy. 24 Conference of the European Wound Management Association EWMA 2014 Madrid Spain Espana. 2014;360.
Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuunemann HJ. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;7-47. doi: 10.1378/chest.1412S3
Naess LA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrom J. Incidence and mortality of venous thrombosis: a population-based study. Thromb Haemost. 2007;692-699. doi: 10.1111/j.1538-7836.2007.02450.x
Walter A, Lorenzo GM. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study. The Lancet Haematology. 2016;3:12-21. doi: 10.1016/S2352-3026(15)00257-4

Close metadata